Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

Abstract

Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.

• Authors: D Papamichael, C J Gallagher, R T Oliver, P W Johnson, J Waxman
• Journal: British journal of cancer (Br J Cancer) Vol. 75 Issue 4 Pg. 606-7 ( 1997) ISSN: 0007-0920 [Print] England
• PMID: 9052419 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents, Phytogenic
• Paclitaxel

Topics

• Adult
• Aged
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Carcinoma, Squamous Cell (drug therapy, pathology)
• Carcinoma, Transitional Cell (drug therapy, pathology)
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Neoplasm Staging
• Paclitaxel (therapeutic use)
• Ureteral Neoplasms (drug therapy, pathology)
• Urinary Bladder Neoplasms (drug therapy, pathology)